BeiGene's BTKi is approved in more than 65 markets globally BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, announced today that BRUKINSA (zanubrutinib), a
BeiGene (BGNE) BRUKINSA Approved in Canada for the Treatment of Chronic Lymphocytic Leukemia streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CLL Canada supports World CLL Day with a colourful ask to Canadians newswire.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswire.ca Daily Mail and Mail on Sunday newspapers.